Impacts of COVID-19 and SARS-CoV-2 on male reproductive function: a systematic review and meta-analysis protocol
Introduction COVID-19 pandemic caused by SARS-CoV-2 has become a global health challenge. SARS-CoV-2 can infect host cells via the ACE2 receptor, which is widely expressed in the corpus cavernosum, testis and male reproductive tract, and participates in erection, spermatogenesis and androgen metabolism. Also, the immune response and persistent fever resulting from COVID-19 may lead to damage of the testicular activity, consequently compromising male fertility. Methods and analysis PubMed, MEDLINE, EMBASE, Web of Science, Cochrane Library, China National Knowledge Infrastructure, China Science and Technology Journal database, Chinese Biomedical Databases and Wanfang Data will be systematically searched for observational studies (case–control and cohort) published up to March 2021 in English or in Chinese literature on the impacts of COVID-19 and SARS-CoV-2 on male reproductive function. This protocol will follow the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols guidelines and Meta-analysis of Observational Studies in Epidemiology. The primary outcome will be semen parameters, and the additional outcomes will include: (a) detection of SARS-COV-2 in semen, (b) male sexual hormones, (c) sperm DNA fragmentation index, (d) erectile function, (e) evaluation of testis and also the male genital tract. Two reviewers will independently extract data from the included studies based on a predesigned data extraction form. The risk of bias of included studies will be evaluated through the Newcastle-Ottawa Scale for observational studies. Review Manager software V.5.3 will be used for statistical analysis. Q statistic and I² test will be performed to assess the heterogeneity among studies. Sensitivity analysis will be used to explore the robustness of pooled effects. We will use the Grading of Recommendations Assessment, Development and Evaluation system to assess the quality of evidence. Ethics and dissemination Ethical approval is not required and results will be published in a peer-reviewed journal. PROSPERO registration number CRD42021245161.
Covid-19 vaikuttaa ihmiskehoon monella tavalla – kliininen tutkimus pyrkii paljastamaan uuden taudin salat
Turun yliopiston professorit Jarmo Oksi ja Ville Peltola seuraavat koronaepidemian kehitystä Turun yliopistollisessa keskussairaalassa, jossa tilanne on vielä suhteellisen rauhallinen. // 6.5.2020
Researchers investigate SARS-CoV-2 specific inflammatory response
New research can confirm that while some of the response from monocytes to SARS-CoV-2 is generic to virus infection, most of it SARS-CoV-2 specific, especially proinflammatory responses. // 7.1.2022
Broad cross-neutralization antibodies found to be effective against SARS-CoV-2 Omicron variant
A new study aimed to explore whether there is a way to induce the production of potent neutralizing antibodies capable of neutralizing all SARS-CoV-2 variants - including Omicron. // 6.1.2022
SARS-CoV-2 appears to persist in organs throughout the body for months
The coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), leads to asymptomatic or mild symptoms in most cases. However, in a significant minority, it causes moderate or severe disease, with lung damage and sometimes multi-organ dysfunction, the origin of which is currently a matter of intense debate. // 6.1.2022
Melatonin found to inhibit SARS-CoV-2 entry into mice brains
New research recently unveiled the utility of melatonin and melatonin-derived medicines in reducing brain entry of severe acute respiratory syndrome coronavirus 2 and subsequently preventing long-term neurological consequences of coronavirus disease 2019. // 6.1.2022
How diet, supplements and lifestyle changes can help battle COVID
A recent editorial in the journal Nutrients emphasizes how efficacious non-pharmacological interventions in conjunction with the promotion of healthy lifestyle and dietary patterns may improve overall health status and reduce the risk of infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), as well as the potential adverse effects of coronavirus disease 2019 (COVID-19). // 6.1.2022
LIVE-AIR trial demonstrates efficacy of Lenzilumab for treatment of COVID patients with decreased oxygen saturation
The LIVE-AIR phase 3 clinical trial is associated with early treatment of hyperinflammatory response with the humanized monoclonal antibody lenzilumab in COVID-19 patients with decreased oxygen saturation. // 6.1.2022
Integrin/TGF-β1 inhibitors highly effective in attenuating COVID-19 severity
New study results suggest that integrin inhibitors have the potential to both prevent infection with SARS-CoV-2, including the Delta and Omicron variants, and to decrease TGF-β levels, resulting in a decrease in COVID-19 severity, hospitalization, and death, especially in vulnerable and unvaccinated populations. // 5.1.2022
Comparison of infectious SARS-CoV-2 from the nasopharynx of vaccinated and unvaccinated individuals
The frequency of SARS-CoV-2 breakthrough infections in fully vaccinated individuals increased with the emergence of the Delta variant, particularly with longer time from vaccine completion. // 4.1.2022
Both symptomatic and asymptomatic COVID-19 associated with increased risk of cardiovascular events
Researcers determine the risk of symptomatic and asymptomatic SARS-CoV-2 infection on post-acute cardiovascular events and all-cause mortality. // 4.1.2022
Exercise performance in vaccinated and unvaccinated individuals previously infected with SARS-CoV-2
A cross-sectional report from Israel demonstrated the protective effect of BNT162b2 mRNA vaccine (Pfizer–BioNTech) even after mild to moderate COVID-19). // 4.1.2022
A large international team of researchers has conducted a crowdsourced cross-sectional study, in which they have investigated the reliability of the olfactory loss (or loss of smell, or anosmia) as a predictor of coronavirus disease 19 (COVID-19). // 30.12.2021
Clinical-grade soluble human ACE2 shown to inhibit SARS-CoV-2 Omicron variant
New study findings show that the clinical-grade soluble ACE2 effectively inhibits the SARS-CoV-2 Omicron variant, which proves the principle of an effective therapeutic approach against Omicron-driven COVID-19 infections. // 30.12.2021
Paradoxical sex-specific patterns of autoantibody response to SARS-CoV-2 infection - Journal of Translational Medicine
Background Pronounced sex differences in the susceptibility and response to SARS-CoV-2 infection remain poorly understood. Emerging evidence has highlighted the potential importance of autoimmune activation in modulating the acute response and recovery trajectories following SARS-CoV-2 exposure. // 30.12.2021
Rapid antigen tests show lower sensitivity for Omicron than for earlier SARS-CoV-2 variants
Researchers carried out an analytical susceptibility test with cultured SARS-CoV-2 Omicron variant in seven antigen-detecting rapid diagnostic (Ag-RDTs). // 29.12.2021
Study suggests saliva swabs may be more suitable for omicron detection
New study findings reveal that saliva samples are more useful than mid-turbinate samples for the accurate detection of omicron infection. // 29.12.2021
Exploring the importance of selenium in COVID-19 patients
In a new study, researchers reviewed research on the role that selenium could play in protecting individuals against coronavirus disease 2019. // 29.12.2021
At least 3 exposures to vaccine or virus needed for minimum protection against SARS-CoV-2 Omicron
Researchers determine the serum neutralizing and binding activity against the SARS-CoV-2 Omicron variant in individuals with different levels of immunity. // 29.12.2021
Pre-existing immunity against influenza can lower SARS-CoV-2 infection burden and spread
A recent study by a team of European researchers demonstrated how antibodies induced by currently circulating influenza A H1N1 strains can cross-react with the important part of the SARS-CoV-2 spike glycoprotein that interacts with the human cell receptor. // 28.12.2021
Researchers discover antibodies that neutralize omicron and other SARS-CoV-2 variants
An international team of scientists have identified antibodies that neutralize omicron and other SARS-CoV-2 variants. These antibodies target areas of the virus spike protein that remain essentially unchanged as the viruses mutate. // 28.12.2021